aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ... aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
4. mkurnalobaze uSualo zedamxedveloba, gansakuTrebiT hospitalSi o fsiqosocialuri daxmareba o pacients miewodos saxelmZRvanelo da broSurebi o pacientebis monawileoba daxmarebis jgufebSi 5. 4. arv toqsiuroba da gverdiTi efeqtebis menejmenti gverdiTi efeqtebi xSiria arv Terapiis dros, gansakuTrebiT proteazas inhibitorebis miRebis dros (ix. cxrili 13). o lopinavir/ritonavirs da nelfinavirs SeuZliaT gamoiwvion diarea o lopinaviri/ritonaviris miReba asocirebulia hiperlipidemiasTan (gansakuTrebiT trigliceridebis momatebasTan) o cximebis metabolizmis darRvevebi SeiZleba gamoiwvios TiTqmis yvela proteazas inhibitorebma o erTaderTi proteazas inhibitori, romelic gavlenas ar axdens lipidur cvlaze aris atazanaviri da atazanavir/ritonaviri. zogierT qveyanaSi atazanaviri mowodebulia mkurnalobis meore rigis sqemaSi o kardiovaskularuli garTulebebis riskis momateba saWiroebs Semdgom Seswavlas cxrili 13 arv-s toqsiurobis dadastureba da menejmenti ARV toqsiuroba menejmenti RviZlis nekrozi nevirapini (NVP) o cxeleba, gamonayari (50%), gulisreva, Rebineba, eozinofilia, alt, ast-s donis momateba o o Cveulebriv pirvel 6-18 kviraSi, iSviaTad 48 kviris Semdeg o o laqtat-acidozi maRlidan dabali riskisken: o stavudini didanozinTan erTad o didanozini o stavudini o zidovudini o o o nevirapinze myofi pacientebis 1-2%, qalebSi CD4 > 250 ; kacebSi CD4 > 400-ze gulisreva, Rebineba, wonaSi dakleba, sisuste, pankreatiti, multiorganuli ukmarisoba, respiratoruli distres sindromi yoveli 1000 pacientidan 1-10 weliwadSi didanozini da stavudini 46 o o o RviZlis funqciuri sinjebis monitoringi 2, 4, 8, 16 kviraze da Semdeg yovel 3 TveSi simptomuri mkurnaloba RviZlis nekrozis mkurnaloba, calkeul klinikur SemTxvevebSi wamlebis Sewyveta laqtat-acidozis monitoringi Tu eWvia, inaxos adreuli indikatorebi (kreatinkinaza (CK) HCO3) acidozis samkurnalod mowodebulia bikarbonati abakaviriT, tenofoviriT, lamivudiniT, emtricitabiniT Secvla
maRali mgrZnobeloba abakaviri (ABC ) o xSirad aris cxeleba, gamonayari, aseve sisuste da gulisreva o 5%, iSviaTad 6 kviris Semdeg stivens-jonsis sindromi, epidermisis toqsiuri nekrozi nevirapini (NVP) efavirenzis dabali o cxeleba, buStukovani gamonayari, mialgia doziT o nevirapini 1%-Si, efavirenzi 0,1%-Si o o o o o kanze dakvirveba, ar SeiZleba dawyeba gamonayris sawinaaRmdego wamlebTan erTad. Sewydes abakaviris miReba da ar ganaxldes Tu diagnozi saeWvoa Seicvalos zidovudiniT, tenofoviriT an stavudiniT kanze dakvirveba antibiotikebis daniSvna Wrilobis samkurnalod pankreatiti maRlidan dabali riskisken: o stavudini didanozinTan erTad o didanozini o stavudini o o tkivili, lipazas maRali done didanozini 1-7%, dozis SemcirebiT o o o lipazas donis monitoringi simptomuri mkurnaloba, parenteraluri kveba, wamlebis Sewyveta zidovudiniT an tenofoviriT an abakaviriT Secvla 47
- Page 1 and 2: aiv infeqcia/SidsiT avadmyofTa mkur
- Page 3 and 4: sarCevi klinikuri saxelmZRvanelo-re
- Page 5 and 6: 3.2.2.cxeleba aiv inficirebulebSi 3
- Page 7 and 8: aiv infeqcia/Sidsis fonze ganviTare
- Page 9 and 10: done mtkicebulebis siZlieris done (
- Page 11 and 12: 1.daavadebis definicia Sidsi abrevi
- Page 13 and 14: Sidsi registrirebulia msoflios 216
- Page 15 and 16: egistrirebul SemTxveevaTa 79% saqar
- Page 17 and 18: adamianis imunodeficitis virusis sa
- Page 19 and 20: aiv rnm-is koncentracia plazmaSi mk
- Page 21 and 22: SeuZlebelia da gadamwyveti misi dia
- Page 23 and 24: persistuli generalizebuli limfadeno
- Page 25 and 26: signalis amplifikacia komplementuri
- Page 27 and 28: • vizitamde rezistentobis testis
- Page 29 and 30: • adamianis papilomavirusi (maxvi
- Page 31 and 32: etinitis identifikaciisTvis, rodesa
- Page 33 and 34: cxrili 8 rekomendaciebi arT dawyebi
- Page 35 and 36: arv medikamentebi arseboben Semdegi
- Page 37 and 38: aCveneben, rom pirveladi rezistento
- Page 39 and 40: - tabletebis Cveneba pacientisTvis
- Page 41 and 42: - aqedan gamomdinare, nrti+anrti re
- Page 43 and 44: igulisxmeba im medikamentebis kombi
- Page 45: X (arv): testebi, romlebic unda Cat
- Page 49 and 50: transaminazebis elevacia anrti (all
- Page 51 and 52: ARV toqsiuroba menejmenti nefrotoqs
- Page 53 and 54: xSiri oportonistuli infeqciebia, ma
- Page 55 and 56: cxrilebis wakiTxvis magaliTi 1. cxr
- Page 57 and 58: damateba2. jandacvis msoflio organi
- Page 59 and 60: damateba 4. ZiriTadi informacia ant
- Page 62 and 63: damateba 5. mkurnalobis reJimis dac
- Page 64 and 65: saerTaSoriso saxeli stavudini (d4T)
- Page 66 and 67: mcire mutacia muSaobs kombinaciaSi.
- Page 68 and 69: 25. Phillips AN et al. Viral load o
- Page 70 and 71: Suppl 2:S171-176. 73. Altice FL, Mo
- Page 72 and 73: 122. Koval CE et al. Immune reconst
- Page 74 and 75: kandidozi dRe yovel dRe - ko-trimoq
- Page 76 and 77: karcinoma (ara SidsTan perikardiuli
- Page 78 and 79: o cxeleba o wonaSi kleba o Ramis of
- Page 80 and 81: indikatorebi filtvis darRveuli funq
- Page 82 and 83: o yvelaze xSirad viTardeba diarea,
- Page 84 and 85: o glukokortikoidebis sistematiuri m
- Page 86 and 87: 100 mg/dReSi meore rigis sqemebi am
- Page 88 and 89: o eqspoziciis Sedegad daavadebis ga
- Page 90 and 91: o remisiis miRweva Zalian Znelia da
- Page 92 and 93: qimioTerapiiT (mag : B-ALL reJimi)
- Page 94 and 95: • imunodeficitis mqone pacientebS
maRali mgrZnobeloba<br />
abakaviri (ABC ) o xSirad aris cxeleba,<br />
gamonayari, aseve sisuste<br />
<strong>da</strong> gulisreva<br />
o 5%, iSviaTad 6 kviris<br />
Semdeg<br />
stivens-jonsis sindromi, epidermisis toqsiuri nekrozi<br />
nevirapini (NVP)<br />
efavirenzis <strong>da</strong>bali<br />
o cxeleba, buStukovani<br />
gamonayari, mialgia<br />
doziT<br />
o nevirapini 1%-Si,<br />
efavirenzi 0,1%-Si<br />
o<br />
o<br />
o<br />
o<br />
o<br />
kanze <strong>da</strong>kvirveba, ar<br />
SeiZleba <strong>da</strong>wyeba<br />
gamonayris<br />
sawinaaRmdego<br />
wamlebTan erTad.<br />
Sewydes abakaviris<br />
miReba <strong>da</strong> ar ganaxldes<br />
Tu diagnozi saeWvoa<br />
Seicvalos<br />
zidovudiniT,<br />
tenofoviriT an<br />
stavudiniT<br />
kanze <strong>da</strong>kvirveba<br />
antibiotikebis <strong>da</strong>niSvna<br />
Wrilobis samkurnalod<br />
pankreatiti<br />
maRli<strong>da</strong>n <strong>da</strong>bali<br />
riskisken:<br />
o stavudini<br />
di<strong>da</strong>nozinTan<br />
erTad<br />
o di<strong>da</strong>nozini<br />
o stavudini<br />
o<br />
o<br />
tkivili, lipazas maRali<br />
done<br />
di<strong>da</strong>nozini 1-7%, dozis<br />
SemcirebiT<br />
o<br />
o<br />
o<br />
lipazas donis<br />
monitoringi<br />
simptomuri <strong>mkurnaloba</strong>,<br />
parenteraluri kveba,<br />
wamlebis Sewyveta<br />
zidovudiniT an<br />
tenofoviriT an<br />
abakaviriT Secvla<br />
47
Change language